- Hypertrophic Cardiomyopathy (HCM)
- Vaccines: 2023 Year in Review
- Eyecare
- Urothelial Carcinoma
- Women's Health
- Hemophilia
- Heart Failure
- Vaccines
- Neonatal Care
- NSCLC
- Type II Inflammation
- Substance Use Disorder
- Gene Therapy
- Lung Cancer
- Spinal Muscular Atrophy
- HIV
- Post-Acute Care
- Liver Disease
- Pulmonary Arterial Hypertension
- Biologics
- Asthma
- Atrial Fibrillation
- Type I Diabetes
- RSV
- COVID-19
- Cardiovascular Diseases
- Breast Cancer
- Prescription Digital Therapeutics
- Reproductive Health
- The Improving Patient Access Podcast
- Blood Cancer
- Ulcerative Colitis
- Respiratory Conditions
- Multiple Sclerosis
- Digital Health
- Population Health
- Sleep Disorders
- Biosimilars
- Plaque Psoriasis
- Leukemia and Lymphoma
- Oncology
- Pediatrics
- Urology
- Obstetrics-Gynecology & Women's Health
- Opioids
- Solid Tumors
- Autoimmune Diseases
- Dermatology
- Diabetes
- Mental Health
Reportcard: State transparency
Report Card on State Transparency Laws
Based on varying levels of price information and public access to information
Alabama F
Alaska F
Arizona F
Arkansas D
California D
Colorado B
Connecticut F
Delaware F
Florida D
Georgia F
Hawaii F
Idaho F
Illinois C
Indiana F
Iowa C
Kansas F
Kentucky C
Louisiana D
Maine B
Maryland F
Mass. A
Michigan F
Minnesota B
Mississippi F
Missouri F
Montana F
Nebraska F
Nevada C
N.H. A
New Jersey F
New Mexico F
New York F
N.C. F
N.D. F
Ohio D
Oklahoma F
Oregon F
Pa. F
R.I. F
S.C. F
S.D. C
Tennessee F
Texas D
Utah C
Vermont C
Virginia B
Washington F
W.V. D
Wisconsin B
Wyoming F
Source: Catalyst For Payment Reform, “Report Card on State Price Transparency Laws,” March 18, 2013
DC Roundtable: Patrick Cooney of The Federal Group Drops the Latest on PBM Legislation in Washington
April 11th 2024In this episode of "DC Roundtable," Peter Wehrwein, managing editor of Managed Healthcare Executive, spoke with Patrick Cooney, president of The Federal Group, a lobbying and strategic planning firm in Washington, D.C., about recent developments in Washington concerning PBMs.
Listen
Drug Discount Programs Poised to Change with New Tech, Pharma Execs Survey Finds
April 22nd 2024It is somewhat mind-boggling in 2024 that more than one-third of pharma organizations still rely on manual entry of data into Excel spreadsheets to track duplicate discounts that can cost millions of dollars a year in lost revenue
Read More
